Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06015503 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

Study acronym: KANNON
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: 157 to 139 · Completion date: Oct 30, 2025 to Dec 30, 2026 · Site details revisedv4 Show 3 more changesShow less
    • Enrollment target: 157 to 139
    • Completion date: Oct 30, 2025 to Dec 30, 2026
    • Site details revised
  2. Primary completion date changed from estimate of Oct 30, 2024 to Mar 6, 2025 Completion date: Sep 9, 2026 to Oct 30, 2025 · Eligibility criteria revisedv3 Show 2 more changesShow less
    • Completion date: Sep 9, 2026 to Oct 30, 2025
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Apr 30, 2024 to Oct 30, 2024v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
It is a phase Ⅱ,open-label, single-line, Multiple cohorts, Multicenter study assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC).
Trial Details
NCT Number NCT06015503
Lead Sponsor Avistone Biotechnology Co., Ltd.
Conditions NSCLC (Non-small Cell Lung Cancer)
Enrollment 139 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov